RecruitingPhase 1NCT05534620

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Studying Hereditary clear cell renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
medac GmbH
Principal Investigator
Ute Eckenbach
SyntheractHCR
Intervention
Treosulfan(drug)
Enrollment
36 enrolled
Eligibility
18-80 years · All sexes
Timeline
20242026

Study locations (4)

Collaborators

Synteract, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05534620 on ClinicalTrials.gov

Other trials for Hereditary clear cell renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary clear cell renal cell carcinoma

← Back to all trials